Free Newsletter
Researchers ready trials for inhalable measles vax
Backed with funds from the Bill and Melinda Gates Foundation, a group of researchers say they're ready to launch human trials of a new inhalable measles vaccine that can be used to guard against the disease in poor countries.
"By taking one deep breath, a child could be efficiently vaccinated," researchers told the American Chemical Society meeting in Washington, D.C. In order to combat measles in underdeveloped countries, the investigators say they need an inhalable vaccine that can be manufactured in powder form for easy transport.
To make the new vaccine, researchers took a weakened form of the measles virus and mixed it with tiny droplets of carbon dioxide, which was then dried into powder form. The hard part was keeping it cheap. But they were able to keep the cost of a single dose to 17 cents and developed an inhaler that costs 10 cents each. And the same technology, they add, could be put to use for influenza vaccines.
- read the story from Red Orbit
Related Articles:
Gates exec calls for equal access to pandemic vaccines
Gates Foundation helps launch $1.5B program
Gates uses mosquitoes to spread his malaria message
Gates to increase spending despite heavy losses
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




